Can the EUnetHTA HTA Core Model ® For Pharmaceuticals Help to Ensure an Aligned View of Value?

Monday June 15 - Oslo Panel 08 Moderator: Luciana Ballini



#HTAiOslo2015

Panellists

Finn Kristensen

EUnetHTA Secretariat Director, Danish Health and Medicines Authority, Denmark

Wim Goettsch

Lead Partner EUnetHTA JA2 WP5 on Rapid Assessments - ZIN, The Netherlands


Jamie Garside Health Outcomes Manager – Roche Products Ltd.

Luciana Ballini Chair of EUnetHTA Plenary Assembly – ASSR, Italy



EUnetHTA at HTAi





HTA Core Model An aligned view of value





Why an aligned view of Value ?

- For an aligned assessment process?
- For aligned outcomes (decisions) ?
- For eliciting assessments/decisions when body of evidence sufficient ?
- For a shared view on evidence generation?
- For common definitions of value AND of lack of value ?





HTA Core Model [®] and Value

- A practical tool for EUnetHTA to implement transational collaborative HTA work that:
- stems from a long and complex process of revision
- is aligned with a shared meaning of value

Intended for <u>an aligned process</u> of assessment of value in order to avoid duplication





HTA Core Model [®] and Value

- Multidimensional view of value
- 9 domains and over 100 questions related to value
- Challenges of non technical / non clinical domains
- Interdependence of domains

Are most elements of value embedded in the Core Model?

Should all domains be developed for the assessment of value at any stage of development of the technology?





What does the HTA Core Model [®] do for Value

- Ensures transparency
- Ensures common assessment process (methods)
- Handles persisting uncertainty
- Aids evidence generation to demonstrate value
- In-built flexibility for future adjustments

Has it improved predictability? Is it fit to encompass future adjustments on value?





What does the HTA Core Model ® do for Value

- Tested by non EUnetHTA research/HTA groups
- Tested by manufacturers
- Basis for common submission template and for Additional Evidence Generation

Does shared use of HTA Core Model facilitate sharing of information on value from product development to product assessment ?





HTA Core Model ® implemented

- Not an academic /theoretical terms of reference
- A working tool tested within:
 - EUnetHTA collaboration at large

Finn Kristensen

- Rapid Relative Effectiveness Assessment (REA)
 Wim Goettsch
- Manufacturer's assessment of developed technology
 Jamie Garside





Summary of perspectives from the Panelists

Finn Kristensen

- An overview of the EUnetHTA Core Model & planned revisions
- EUnetHTA Core Model Benefits and limitations
- The model is not yet established amongst stakeholders Wim Goettsch
- The REA experience to date
- Do we wish to develop an aligned view of value amongst HTA bodies, payers, Pharmaceutical industry and Regulators?
- The future approaches for rapid REA & potential for a common framework of value

Jamie Garside

- Roche experience of the EUnetHTA Core Model
- Examples of where broader value would be helpful in HTA assessments

